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Abstract  
Background: isoflavones possess both anti-estrogenic and estrogenic-like properties. Many 
traditional dishes from Indonesia are rich in isoflavones, such as tempeh, tofu, and soymilk. It 
remains controversial whether women diagnosed with breast cancer should be advised to avoid or 
increase the intake of isoflavone food to improve survival.  
Objective: to identify the association between post cancer diagnosis isoflavone food consumption 
with the recurrence and survival rate among women with breast cancer.   
Methods: the search was conducted with advanced searching on PubMed, Cochrane, Scopus, and 
ProQuest according to the clinical question. The screening of title and abstract using inclusion and 
exclusion criteria, double filter, and reading full text led to six useful articles. The selected studies 
were critically appraised for validity, importance, and applicability.  
Results: five prospective cohort studies and one meta-analysis were found with comparable 
validity. Women at the high level of isoflavone intake (>10 mg/day) had a significant reduction in 
the risk of recurrence and mortality of breast cancer.  
Conclusion: isoflavone food intake is associated with better survival, low recurrence, and low 
mortality among both  ER-positive and ER-negative breast cancer patients.  
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Introduction 
 
Breast cancer is the most common malignancy 
affecting women, and its incidence and mortality 
rate is increasing worldwide. The prevalence of 
breast cancer in Asian countries, including 
Indonesia has been rapidly increasing during the 
past few decades.1 Migration studies have shown 
that breast cancer incidence in Asian women 
becomes similar to that of Western women because 
of westernization diet. The GLOBOCAN study in 
2018 reported for 17% of new cases and 11% of 
mortality rate of breast cancer each year.2 The 
number of women who develop breast cancer is 
more than two times the number of women who die 
of breast cancer, and this is thought to be related to 
the relatively high survival rate. Therefore, breast 
cancer survivors are expected to improve their 
quality of life through optimal nutrition.  
Isoflavones show both anti-estrogenic and 
estrogenic-like properties. In Asian countries, the 
average daily intake of isoflavones is 25–50 mg, 
while in the United States and Europe is less than 3 
mg.3 Isoflavone has been suggested to inhibit breast 
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cancer development by decreasing estrogen 
production and inhibiting cell proliferation.4, 5 
However, isoflavones may exert an estrogenic effect 
by binding to estrogen receptors in the breast and 
enhance cellular proliferation.4, 6 As a consequence, 
clinicians frequently suggest women with breast 
cancer to either avoid isoflavone foods entirely or 
use them in moderation. Isoflavone containing foods 
are easily found in Indonesia, such as tempeh and 
tofu.7, 8 Consumption of that product is high because 
of the high nutritional value, easy preparation, and 
affordable price. Tempeh is contained the highest 
amount of total isoflavone (daidzein and genistein) 
compared to other soy products.7  
Data on the association of post-diagnosis 
isoflavone food consumption with breast cancer 
prognosis are still conflicting. Experimental studies 
suggest that isoflavones may interact with tamoxifen 
therapy, with some studies showing a potential 
benefit of combined dietary isoflavone intake and 
tamoxifen use on the inhibition of breast cancer 
growth, whereas other studies have reported a 
reduction in the anti-cancer effects of tamoxifen on 
breast tissue.6, 9, 10 A concern has been raised 
whether women should be advised to avoid or 
increase intake of isoflavone food to inhibit cancer 
progression. Therefore, we conducted the evidence-
based case report to critically evaluate the effect of 
isoflavones food consumption on the recurrence and 
mortality rate among women with breast cancer 
from different ethnicities. 
 
Clinical question  
 
A-52 years old woman admitted to the clinic after 
being referred by an oncologist with a decrease in 
food intake and three kilograms of weight loss 
within one month. She was diagnosed with stage 
IIIB breast cancer six months ago and had 
undergone a right radical breast mastectomy and 
chemotherapy. The patient was malnourished. 
Previously, she liked to consume tempeh or tofu 
until the doctor advised her to avoid intake of 
isoflavone foods (tempeh, tofu, or soybeans) to 
inhibit her breast cancer progression. 
In women with breast cancer, does consumption of 
isoflavone foods cause a higher risk of breast cancer 
recurrence or increase mortality? 
 
Methods 
 
A search of  literature was done on March, 15st 2020 
in four databases including Pubmed, Cochrane, 
Scopus, and ProQuest using terminology listed in 
Table 1. The results obtained from four sites were 
screened by title and abstracts using inclusion and 
exclusion criteria, double filter, and checked for full-
text availability. Eligible articles were cohort 
prospective, meta-analyses, and systematic reviews 
that point breast cancer prognosis (recurrence, 
survival, and mortality rate) as the primary outcome. 
Review articles were excluded. The search strategy, 
inclusion-exclusion criteria, and results shown in 
Figure 1. After article selection, a critical appraisal 
was done by two authors using guidance for 
prognostic study from the Center of Evidence-Based 
Medicine.  
 
Results 
 
Following the search strategy, six original articles 
were eligible for this evidence-based case report. 
Two of them (Zhang YF et al., 2012 and Kang HB 
et al., 2012) were from China; three studies (Caan 
BJ et al., 2011; Nechuta et al., 2012; and Zhang F et 
al., 2017) from US, Canada, and Australia; also one 
meta-analyses among Asian-American women (Chi 
et al., 2013). Characteristic for stratification, 
determinant, and results are available in Table 2. The 
critical appraisal is shown in Table 3. Five articles 
were cohort prospective with a level of evidence 2 
and one article was meta-analysis by Chi and 
colleagues with a level of evidence 1. All studies 
considered to have good validity, although the study 
groups of Zhang, et al.5 were not similar. The groups 
were clearly defined and had an adequate follow-up 
time. From the aspect of importance and 
applicability, all studies had a relative risk (RR) 
below 1, which means that higher consumption of 
isoflavone foods did not increase the risk of 
recurrence and mortality rate among women with 
breast cancer. 
 
Discussion 
 
Soybean is rich in isoflavones, which are 
phytoestrogens with potent anticancer effects.11 
Isoflavones possess anti-estrogenic and 
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nonhormonal properties that enable them to inhibit 
the development of breast cancer by decreasing 
estrogen production, inhibiting cell proliferation, 
and reducing reactive oxygen species (ROS).5 
Furthermore, isoflavones have anti-angiogenic, 
activation of natural killer (NK) cells, and 
antioxidants effects.1 Experimental studies suggest 
that isoflavones may interact with tamoxifen, with 
some studies showing a potential benefit of 
combined dietary isoflavone and tamoxifen therapy 
on the inhibition of breast tumor growth.6, 12 Several 
reports indicate that the occurrence of breast cancer 
is considerably lower in Asian individuals compared 
with other populations because of high levels of 
isoflavones as part of their regular diet.3 
Controversy regarding the implementation of 
dietary isoflavones for breast cancer patients is still 
debatable. Other than anti-estrogen activity, 
isoflavones may have estrogen-like properties 
including the ability to bind to estrogen receptor (ER) 
in the breast and stimulate cellular proliferation.6 
Taylor et al.13 showed that isoflavones may enhance 
the proliferation of breast cancer cells in-vitro. 
Therefore, clinicians frequently suggest breast 
cancer patients to avoid isoflavone foods, especially 
in women with estrogen-sensitive breast cancer. The 
three isoflavones (genistein, daidzein, and glycitein) 
account for approximately 50%, 40%, and 10%, 
respectively, of the total isoflavone content. Each of 
them has different ER binding affinities and 
genistein is considered to be the most potent.14 
Genistein has been shown to enhance the 
proliferation of breast cancer cells in vitro; 
specifically in ER-positive and promote estrogen-
dependent mammary tumor growth in animal 
studies.15, 16  
Critical appraisal of six literatures shows no 
increase in recurrence or mortality among breast 
cancer patients with high isoflavones consumption. 
Otherwise, several studies indicate significantly 
lower risk of recurrence, metastasis, development of 
new breast cancer, and mortality with high 
isoflavones consumption.5, 6, 10, 17, 18 This association 
was observed across all ethnics groups. A 
prospective study conducted by Shu et al.15 showed 
that Asian women who continued to consume soy 
after being diagnosed with breast cancer had 
significantly lower levels of recurrence compared 
with women who consumed little to no soy. 
Likewise, a report by Guha and colleagues in 1954 
Californian female breast cancer survivors found a 
trend for a reduced risk of cancer recurrence with 
increasing quintiles of daidzein and glycetin intake 
among postmenopausal women (p=0.08 for 
daidzein, p=0.06 for glycetin).19 In analyses 
stratified by ER status; tamoxifen therapy; and 
menopausal status, we found the inverse association 
of isoflavone intake with recurrence and mortality 
appeared among all women with breast cancer. Only 
one study, Can et al.4 showed the non-statistically 
significant reduction of mortality rate among breast 
cancer women with consumption of isoflavones 
>16.3 mg/day. Furthermore, there were no negative 
effects from consumption of isoflavones >35 
mg/day or equivalent to the average consumption in 
Asia. 
 Isoflavones are usually present in the form of 
glycosides in soy foods. Isoflavones glycosides have 
a complex structure, it needs biochemical processes 
to simplify the structure so it will easily absorb. 
After being ingested, isoflavones are hydrolyzed to 
aglycones and carbohydrates by β-glucosidase and 
other enzymes in the lower small intestine.7 
Aglycones are absorbed from the intestinal tract by 
the actions of intestinal bacteria. Therefore, inter-
individual variability in isoflavone metabolism 
might be depending on intestinal flora.10 Daidzein 
can be further metabolized to dihydrodaidzein, 
equol, and O-desmethylangolensin which has a 
higher biological activity compounds.1, 7 However, 
individual differences exist in this conversion 
ability, depending on ethnicity, lifestyle, and genetic 
polymorphisms.1, 6  
Traditional soy foods contain approximately 3.5 
mg of isoflavones per gram of protein and highly 
processed soy can lose as much as 80% of its 
isoflavone content. On average, traditional soy foods 
contain 20-30 mg of isoflavones per serving (e.g 250 
mL of soymilk made from whole soybeans or 100-
gram tofu or 75-gram tempeh).14 Asian diet is rich 
in soy products. Isoflavones are present in a variety 
of soy foods but significantly higher amounts are 
found in tempeh. Tempeh is a traditional fermented 
product, which often used Rhizopus oligosporus, R. 
microsporus, or R. oryzae for its fermentation. 
Fawwaz, et al.20 show that genistein level in tempeh 
is 5 times higher compared with soymilk. That 
finding proves that the fermentation process can 
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release sugar on isoflavones to produce genistein. 
The content of daidzein and genistein in tempeh will 
increase with 3 days fermentation process. After the 
third day, the growth in the amounts of aglycones 
was not statistically important. Generally, 
depending on the strain, the content of genistein in 
the fermented product was 8-10 times higher than in 
unfermented product and the fermentation process 
will increase their bioavailability.7 
Isoflavones show a competitive role with 
endogenous estrogens in estrogen binding receptors. 
This would increase the synthesis of sex hormone-
binding globulin (thus lowering the biological 
availability of sex hormones), inhibit 17β-
hydroxysteroid dehydrogenases (thus reducing 
estrogen synthesis), and increase clearance of 
steroids from the circulation. This anti-estrogenic 
effect may play a positive role in better breast cancer 
outcomes.18 Another speculation that the positive 
result of breast cancer recurrence is dependent on 
differential gene expression induced by the 
isoflavones.16 In our case report, the high intake of 
isoflavones was positively associated with a better 
prognosis, which was in line with the previous 
hypothesis.  
Several studies in this case report have examined 
the effect of soy intake with stratification by ER but 
reported different findings. The possible 
anticarcinogenic effect of isoflavones comes from 
their anti-estrogenic or estrogenic activity mediated 
by their affinity for ER. However, isoflavones can 
exert hormonal and anti-estrogenic effects in many 
ways independently of the ER, and thus further 
studies are needed to elucidate the underlying 
mechanism.18 Tamoxifen is an anti-estrogen widely 
prescribed to women with ER-positive tumors as 
long-term adjuvant therapy to prevent recurrences. 
Experimental studies suggest that isoflavones may 
interact with tamoxifen therapy with inconsistent 
findings.18 In this case report, we did not identify 
any bad effects on recurrence and mortality for those 
breast cancer patients who use tamoxifen. 
 
Conclusions 
 
In conclusion, some studies showed that dietary 
intake of isoflavone is safe and was associated with 
lower recurrence and mortality among both  ER-
positive and ER-negative breast cancer patients. 
However, it required further studies to ensure its 
interaction with anti-cancer therapy. The results of 
the study could be applied in Indonesia because most 
studies include Asian ethnic breast cancer women as 
subjects. Research showing that approximately 10 
mg/day of isoflavones is required to inhibit breast 
cancer recurrence. Breast cancer patients may 
beneficially advise to consume one portion of 
isoflavone foods (e.g 75 g tempeh, 100 g tofu, or 250 
mL soy milk each day) and avoiding high processing 
methods. 
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Table 1. Terminology used in four database 
Database Terminology  Hits Results 
Pubmed  (((((((((isoflavone [MeSH Terms]) OR isoflavone [Title/Abstract]) OR 
tempeh[MeSH Terms]) OR tempeh[Title/Abstract]) AND (((((((((breast 
cancer[MeSH Terms]) OR breast cancer[Title/Abstract]) OR breast neoplasm[MeSH 
Terms]) OR breast neoplasm[Title/Abstract]) OR breast carcinoma[MeSH Terms]) 
OR breast carcinoma[Title/Abstract]) AND (((((surviv*[MeSH Terms]) OR 
surviv*[Title/Abstract]) OR prognos*[MeSH Terms]) OR prognos*[Title/Abstract])  
Filters: Free full text; published last 10 years; Humans; English 
38 3 
Cochrane  #1 MeSH descriptor = isoflavone OR tempeh, N= 758 
#2 MeSH descriptor = breast cancer OR breast neoplasm OR breast carcinoma, N= 
36064 
#3 MeSH descriptor =  survival OR prognosis, N=121186 
#4 = #1 AND #2 AND #3, N= 9 
7 2 
Scopus TITLE-ABS-KEY ("isoflavone" OR "tempeh" AND "breast cancer" OR “breast 
neoplasm” OR "breast carcinoma" AND "survival" OR 
"prognosis") AND (LIMIT-TO (ACCESSTYPE(OA) ) ) AND ( LIMIT 
TO ( PUBSTAGE , "final" ) ) AND ( LIMIT 
TO (DOCTYPE, "ar")) AND (LIMIT 
TO (SUBJAREA, "MEDI")) AND (LIMIT-TO (LANGUAGE, "English"))   
23 4 
ProQuest ab (isoflavone OR tempeh) AND ab("breast cancer" OR “breast neoplasm” OR 
"breast carcinoma") AND ab(prognosis OR survival) 
15 1 
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 Table 2. Design and results of the selected articles 
Articles, 
year  
Stratification analysis Determinant Results 
Caan. BJ et 
al 
2011 
Analyses stratified by: 
1. ER/PR status 
(ER+/PR+ ER−/PR−) 
2. Tamoxifen use (yes or 
no) 
A second breast 
cancer event (local 
and distant 
recurrences and 
new breast 
primaries) and all-
cause of mortality  
- Isoflavone intake was unrelated to the risk of a 
second breast cancer event overall (0.78; 95% CI: 
0.46-1.31) or within strata of women defined by 
hormone receptor status or tamoxifen therapy. 
- The risk of death tended to be lower as isoflavone 
intake increased. Women at the highest level of 
isoflavone intake (>16.3 mg/day) had a non-
significant 54% reduction in risk of death compared 
with the lowest quintile (0.46; 95% CI:0.2-1.05, P for 
trend= 0.02). 
 
Kang. HB et 
al 
2012 
 Analyses not stratified by 
menopausal status, ER/PR 
status, and tamoxifen use  
Survival time 
which calculated 
from the date of 
diagnosis to the 
date of last follow-
up from any 
causes and cancer-
specific death 
- The highest soy isoflavone intake (>35.3 mg/day) 
was associated with a decreased death risk of breast 
cancer (OR= 0.25, 95% CI: 0.09-0.54).  
 
 
 
 
 
 
Nechuta. SJ 
et al 
2012 
Analyses stratified by: 
1. Menopausal status (pre 
and postmenopausal) 
2. ER status (ER+ or 
ER−) 
3. Tamoxifen use in ER+ 
breast cancer (yes or 
no) 
Total mortality, 
breast cancer-
specific mortality, 
and recurrences 
(or metastasis or 
development of 
new breast cancer) 
- Consumption of ≥10 mg isoflavone/day was 
associated with a significantly reduced risk of 
recurrence (HR: 0.75; 95% CI: 0.61-0.92) but a non-
significantly reduced risk of all-cause and breast 
cancer-specific mortality. The inverse association 
appeared to be stronger among postmenopausal, 
ER− and tamoxifen use. 
- In China, consumption of ≥10 mg/day was 
associated with a marginally significant reduced risk 
of recurrence compared with < 4 mg/day (HR: 0.59; 
95% CI: 0.47-1.01; p= 0.06), while in the US the 
reduction was significant (HR: 0.76; 95% CI: 0.58-
0.99).  
-  
Zhang. YF 
et al 
2012 
Analyses stratified by ER 
status (ER+ or ER−) 
 
Survival time 
which was 
determined from 
the time of biopsy 
proven diagnosis 
to cancer-specific 
death 
- The average intake of soy isoflavone >17.32 mg/day 
was associated with reduced breast cancer-specific 
death (HR: 0.64; 95% CI: 0.45-0.93) and the trend of 
survival was increased with the increasing dosage of 
soy isoflavone. Better prognosis of breast cancer was 
found among women with ER+ breast cancer (HR: 
0.59; 95% CI: 0.40-0.93) 
-  
Chi et al 
2013 
Analyses stratified by: 
1. ER status (ER+ or 
ER−) 
2. Menopausal status 
((pre and 
postmenopausal) 
3. Tamoxifen use  
Recurrence and 
mortality in breast 
cancer patient  
- Soy isoflavone intake >17.32 mg/day was associated 
with reduced mortality compared with <7.56 mg/day 
(HR: 0.64; 95% CI: 0.45-0.92), especially in ER−, 
ER+, premenopausal,  postmenopausal, and  patients 
with tamoxifen. 
-  
- Soy isoflavones were associated with reduced 
recurrences at consumption >10 mg/day compared 
with  <4 mg/day (HR: 0.74; 95% CI: 0.59-0.92). The 
highest soy foods intake after diagnosis was 
associated with reduced recurrence (HR: 0.74, 
95%CI: 0.64-0.85) compared with the lowest intake, 
especially in ER− and postmenopausal or patients 
with tamoxifen. 
   -  
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Table 2. Design and results of the selected articles (continued) 
Articles, 
year  
Stratification analysis Determinant Results 
Zhang. FF, 
et al 
2017 
Analyses stratified by: 
1. Tumor hormone 
receptor status 
(ER+PR+, ER+PR−, 
ER−PR+ and 
ER−PR−) 
2. Hormonal therapy 
3. Race/ ethnicity (non-
hispanic white, blacks, 
hispanics, Asians) 
4. Menopausal status 
(pre and post) 
All cause of 
mortality  
- Women in the highest quartile of isoflavone intake 
(≥1.5 mg/day) had a 21% decrease in all-cause 
mortality compared to women in the lowest quartile 
(<0.3 mg/day) (Q4 vs. Q1: HR: 0.79, 95% CI: 0.64-
0.97) 
- In stratified analyses, reduced risk of all-cause 
mortality associated with high isoflavone intake 
was statistically significant for women with 
ER−/PR− tumors (HR:0.49, 95% CI: 0.29-0.83) 
and women who did not receive hormonal therapy 
(HR:0.68, 95% CI: 0.51-0.91) 
CI= confidence interval; ER= estrogen receptor; PR= progesteron receptor; HR= hazard ratio; mg= miligram; OR= odds 
ratio; Q= quartile 
 
Table.3 Critical apprisal of the six studies based on criteria by Center of Evidence-Based Medicine, Oxford 
University 
 Validity     
Articles 
Co
m
m
on
 p
oi
nt
 
Fo
llo
w
 u
p 
O
ut
co
m
e 
A
dj
us
tm
en
t 
O
ut
co
m
e 
ov
er
 
tim
e 
Pr
ec
isi
on
 
A
pp
lic
ab
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ty
 
Cl
in
ic
al
ly
 
im
po
rta
nt
 
Level of 
Evidence* 
Caan.BJ et al + + + + - + + + 2 
Kang.HB et al + + + + + + + + 2 
Nechuta.SJ et al + + + + - + + + 2 
Zhang.YF et al + + + + - ? + + 2 
Chi et al + + + + - ? + + 1 
Zhang.FF et al - + + + - + ? + 2 
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Pubmed 
N=38
Sc
re
en
in
g 
Record after Duplicates Removed
N=56
Id
en
tif
ic
at
io
n Cochrane 
N=7 
Scopus
N=23 
ProQuest
N=15 
Screening Title and Abstract 
Inclusion Criteria:
- Women with breast cancer and have 
  received therapy 
- Isoflavone consumption post cancer
  diagnosis
- Outcome: recurrence and mortality
- Meta-analyses and cohort
- Article in english 
- Human studies
- Published in 10 years
Exclusion Criteria:
- In-Vitro studies 
- Full text not 
  available
- Review articles
Eligibility Screening and Reading Full-Text
El
ig
ib
ili
ty
 
In
cl
us
io
n
N= 10
Useful Articles 
N=6
Figure 1. Flowchart of search strategy 
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